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Nasopharyngeal carcinoma (NPC) is an EBV-associated epithelial malignancy prevalent in southern China.
Presence of treatment-resistant cancer stem cells (CSC) may associate with tumor relapse and metastasis in
NPC. ICG-001 is a specific CBP/b-catenin antagonist that can block CBP/b-catenin-mediated transcription
of stem cell associated genes and enhance p300/b-catenin-mediated transcription, thereby reducing the
CSC-like population via forced differentiation. In this study, we aimed to evaluate the effect of ICG-001 on
the CSC-like population, and the combination effect of ICG-001 with cisplatin in the C666-1 EBV-positive
NPC cells. Results showed that ICG-001 inhibited C666-1 cell growth and reduced expression of
CSC-associated proteins with altered expression of epithelial-mesenchymal transition (EMT) markers.
ICG-001 also inhibited C666-1 tumor sphere formation, accompanied with reduced SOX2hi/CD44hi
CSC-like population. ICG-001 was also found to restore the expression of a tumor suppressive
microRNA-145 (miR-145). Ectopic expression of miR-145 effectively repressed SOX2 protein expression
and inhibited tumor sphere formation. Combination of ICG-001 with cisplatin synergistically suppressed
in vitro growth of C666-1 cells and significantly suppressed growth of NPC xenografts. These results
suggested that therapeutically targeting of the CBP/b-catenin signaling pathway with ICG-001 can
effectively reduce the CSC-like population and combination with cisplatin can effectively suppress the
growth of NPC.
N asopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharynx. It has arelatively high prevalence in southern China with an annual incidence of .20 per 100,0001. NPC isconsistently associated with Epstein-Barr virus (EBV) latent infection. The EBV-encoded genes and
cellular microRNAs (miRNAs) are believed to be involved in the pathogenesis of NPC2. C666-1 is the only EBV-
positive NPC cell line carrying native EBV genome and is preferred as a suitable model for translational study of
EBV-associated NPC3. Currently, the standard treatment for NPC is radiotherapy or combined chemo-
radiotherapy with cisplatin-based regimens4. Although primary NPC can be successfully treated with
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radiotherapy and chemo-radiotherapy, the treatment outcomes for
locally advanced and metastatic NPC remains unsatisfactory. High
rates of local relapse and distant metastasis are the major concern for
treatment failure5. Accumulating evidence suggested that a subpo-
pulation of cancer cells with self-renewal and stem-like cell prop-
erties, namely cancer stem cells (CSCs), play an important role in
tumor initiation and resistance to radio- and chemotherapy6,7. The
existence of CSCs may explain the high rate of tumor relapse after
standard therapies8. Therapeutic targeting of the CSC population is a
novel strategy to overcome therapeutic resistance and tumor relapse
after cancer treatment9,10.
Wnt signaling is one of the key CSC self-renewal signaling path-
ways11. Multiple stem cell-related genes such as CD44, survivin, and
c-myc areWnt-regulated genes. Early studies on the gene expression
profile of NPC showed that the expression of a number of Wnt
signaling components, including wingless-type MMTV integration
site family, member 5A (Wnt5A), Frizzled homolog 7 (FZD7),
b-catenin, and CREB-binding protein (CBP) are frequently
activated, and the aberrant increased expression of b-catenin is
associated with poor prognosis in NPC12–14. In addition to the over-
expression of theWnt components, epigenetic inactivation of tumor
suppressor Wnt inhibitory factor-1 (WIF-1) was also found to be
involved in the activation of the Wnt pathway and the metastasis of
NPC15,16. In NPC, the Wnt signaling pathway was aberrantly acti-
vated and the expression of the Wnt-regulated stem cell associated
genes was also found to be up-regulated17. To achieve a better trans-
lational outcome, therapeutic targeting of the Wnt signaling in NPC
may reduce the CSC population and, therefore, sensitize the cells to
conventional treatment.
Small molecules targeting the Wnt signaling pathway have
recently been introduced to pre-clinical and clinical studies18,19.
Kahn and co-workers have previously found that ICG-001, a small
molecule Wnt modulator, can safely eradicate the drug-resistant
CSC-like population and initiate cell differentiation in leukemia
and solid cancer models20–22. In the canonical Wnt pathway, nuclear
b-catenin binds to the coactivator CBP to mediate transcription of
genes associated with stem cell proliferation and cell pluripotency.
ICG-001 binds specifically to CBP and acts as a CBP/b-catenin ant-
agonist, which blocks transcription of genes associated with stem cell
proliferation and self-renewal, thereby reducing the stem cell popu-
lation. This also facilitates the interaction of b-catenin with the
highly homologous coactivator p300 to initiate transcription of genes
associated with cell differentiation23,24. As Wnt signaling is deregu-
lated in NPC, we hypothesized that pharmacological intervention of
Wnt signaling with the CBP/b-catenin antagonist ICG-001 could be
used to reduce the CSC-like population. Here, we studied the effect of
ICG-001 on growth of the EBV-positive C666-1 CSC-like population
through 3-D tumor sphere formation assay. We also found that the
growth inhibitory effect of ICG-001 is correlated with the downre-
gulated expression of the NPC CSC-like markers SOX2 and CD44,
and the upregulated expression of the tumor suppressivemicroRNA-
145 (miR-145). Combination of ICG-001 with the conventional drug
cisplatin showed a synergistic growth inhibitory effect on the C666-1
cell growth and significant tumor suppressive effect on C666-1 and
xeno-2117 EBV-positive NPC xenograft models. This study provides
evidence for use of CBP/b-Catenin antagonists (i.e. ICG-001 or PRI-
724) as potential CSC-targeting drugs and the combination effect
of ICG-001 with conventional therapy in the improvement of
treatment outcome in NPC.
Results
Growth inhibitory effect of ICG-001 on C666-1 EBV-positive
NPC cells. The cell growth assay was initially used to evaluate the
effects of ICG-001 on C666-1 cells. Figure 1a showed the number of
untreated control C666-1 cells reaching a maximum plateau level at
3 to 5 days after incubation. However, the growth of C666-1 was
significantly inhibited by 10 mM ICG-001 (*p,0.05). We next
studied the effect of ICG-001 on the expression of cell growth and
CSC associated proteins. In Figure 1b, Western blotting analysis
showed that ICG-001 downregulated the expression of SOX2,
CD44, survivin, EGFR, FOXM1, and EZH2 in C666-1 after 7 days
of treatment. The growth inhibitory effects of ICG-001 clearly
correlated with the downregulated expression of a group of
proteins associated with the development of CSCs in C666-1.
Epithelial-mesenchymal transition (EMT) has been implicated in
the transition process of CSC formation25. Next, we studied the
expression of EMT markers in ICG-001-treated C666-1 cells.
Western blot analysis showed the re-expression of E-cadherin
(epithelial marker) and decreased expression of vimentin
(mesenchymal marker) after 7 days of ICG-001 treatment
(Figure 1c). This result indicates that ICG-001 decreases the
mesenchymal stem-like phenotype and increases the differentiated
epithelial status of the NPC cells.
ICG-001 inhibits the growth of tumor spheres. Next, the tumor
sphere formation assay was employed to study the effect of ICG-001
on the growth of CSC-like cells. The tumor sphere formation assay is
frequently used as an in vitro assay to enrich CSC-like cells under
the 3-D culturing condition for functional studies26. In this study,
C666-1 cells were incubated with ICG-001 for 7 days and the number
and diameter of tumor spheres were quantified. Results in Figure 2a
Figure 1 | Effect of ICG-001 on the growth of EBV-positive C666-1 cells.
(a) Cell growth assay. Total number of viable cells was counted on days 3, 5,
and 7 after ICG-001 treatment. Results were expressed as the mean 6 S.D.
of three experiments; *p , 0.05. (b) Western blotting analysis of SOX2,
CD44, Survivin, EGFR, FOXM1, and EZH2 expression on day-7.
(c) Western blotting analysis of epithelial-mesenchymal transition (EMT)
markers, E-cadherin and vimentin on day-7. The gels have been run under
the same experimental conditions with different percentage of gels. The
full-length blots were presented in the supplementary Figure S1.
www.nature.com/scientificreports
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showed that ICG-001 significantly (**p,0.02) inhibited the
formation of tumor spheres. A clear inhibition of both number
and size of tumor sphere formation were found after the
treatment. To further study the effect of ICG-001 on the growth of
established tumor spheres, C666-1 cells were allowed to grow and
form tumor spheres without any treatment for 7 days. The
established tumor spheres were then incubated with ICG-001 for
another 7 days. Both the number and diameter of tumor spheres
were measured and presented as a tumor sphere size profile.
Results in Figure 2b showed that the majority of the ICG-001-
treated tumor spheres remained small, with a mean diameter of
31 mm, while the majority of the untreated tumor spheres
continued to grow as the size profile shifted to larger diameters,
with a mean diameter of 55 mm. This observation indicated that
ICG-001 effectively inhibited the further expansion of tumor
spheres in the 3-D culture.
ICG-001 reduced SOX2 and CD44 expression in C666-1 tumor
spheres. In NPC, both SOX2 and CD44 have been shown to be
enriched in the sphere-forming CSC-like populations27. After
C666-1 tumor sphere growth analysis, the expression of SOX2 and
CD44 by the spheroid cells was analyzed using confocal microscopy.
A mild to strong immunoreactivity of SOX2 (red) staining in the
nucleus and CD44 (green) staining in themembrane was observed in
the spheroid cells obtained from the control culture (Figure 3a). The
immunoreactivity of SOX2 and CD44 was greatly reduced in the
spheroid cells after the treatment of ICG-001. Quantitative
expression of SOX2hi and CD44hi population of the spheroid cells
was also determined by Fluorescence-activated Cell Sorting (FACS)
analysis. Figure 3b shows the dot-plot of SOX2hi/CD44hi population.
The results were gated against the non-stained tumor sphere cells
and quantified in the bar chart. There was a 5-fold reduction of the
SOX2hi/CD44hi population after ICG-001 treatment (*p,0.05).
Involvement of SOX2 in the growth of C666-1 tumor sphere
formation. The involvement of CD44 in tumor sphere formation
has been well-characterized in EBV-positive NPC cells27, while the
involvement of SOX2 in tumor sphere formation has not been
studied in EBV-positive NPC cells. SOX2 is one of the major
transcription factors involved in the maintenance of the stem cell
pluripotency28. Overexpression of SOX2 has been implicated in the
regulation of mammosphere formation in the breast cancer model29.
In the present study, we determined the role of SOX2 in C666-1
tumor sphere formation by using SOX2 siRNA. Figure 4a showed
Figure 2 | Effect of ICG-001 on the growth of C666-1 in the 3-D tumor sphere formation and tumor sphere growth assay. (a) Effect on the tumor sphere
formation. ICG-001was added on day 0, when plating the cell into ultra-low attachment plate. The number and size of tumor sphere formed fromC666-1
with and without ICG-001 treatment were compared. (b) Effect on the growth of established spheroids. Tumor spheres were allowed to form for 7 days,
then the established tumor spheres were incubated with ICG-001 for another 7 days. The number and diameter of tumor spheres measured were
presented as tumor sphere size profiles. Results were expressed as the mean 6 S.D. of three experiments; **p , 0.02.
www.nature.com/scientificreports
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that the expression of SOX2was reduced in C666-1 after transfection
with SOX2 siRNA. After knockdown of SOX2 expression, Figure 4b
shows both the number and the diameter of the tumor spheres
were significantly reduced in the tumor sphere formation assay
(**p,0.02). This finding indicated that SOX2 is involved in the
regulation of growth of the sphere.
ICG-001 restoredmiR-145 expression, which repressed SOX2 and
inhibited tumor sphere formation in C666-1. Recent study
suggested the enrichment of SOX2 expression in tumor spheres
may be due to loss of the SOX2 repressing miRNAs27. Therefore,
we studied the expression of SOX2 repressing miRNAs in
NPC cells after ICG-001 treatment. MiR-145 is a known SOX2-
repressing miRNA downregulated in NPC tissue30,31. Realtime PCR
results in Figure 5a show that ICG-001 could significantly restore
miR-145 expression in both the EBV-positive C666-1 and EBV-
negative HONE1 and HK-1 NPC cell lines (*p,0.05). Next, a
SOX2 3’UTR luciferase reporter assay was used to further validate
Figure 3 | ICG-001 reduced SOX2 and CD44 expression in C666-1 tumor sphere. (a) Confocal staining showing pseudocolor red for SOX2 and green
for CD44. Loss of both SOX2 and CD44 expression was observed in ICG-001-treated C666-1 tumor sphere. (b) FACS analysis of spheroid cells stained
with Alex FluorH 647 conjugated SOX2 and Alexa FluorH 488 conjugated CD44 and gated against the non-stained tumor sphere cells. The SOX2hi/CD44hi
population was significantly decreased after ICG-001 treatment. Results were expressed as the mean 6 S.D. of three experiments; *p , 0.05.
www.nature.com/scientificreports
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the suppressive action of miR-145 on SOX2 expression in C666-1.
Figure 5b shows that cotransfection of miR-145 precursor and SOX2
3’UTR reporter effectively reduced luciferase activities compared to
miR-precursor control (**p,0.02). Results in Figures 5c and 5d
demonstrate that transfection of miR-145 precursor resulted in the
downregulated expression of the SOX2 protein in C666-1 (*p,0.05).
The number and size of C666-1 tumor sphere formation were also
significantly suppressed (*p,0.05). Taken together, ICG-001 was
found to inhibit the CSC-like population through restoration of
miR-145, which directly binds to SOX2 3’UTR and represses SOX2
expression in C666-1 NPC cell line.
Synergistic growth inhibitory effect of ICG-001 and cisplatin on
C666-1 cells.The existence of chemo-resistant CSC-like populations
within the bulk tumor is believed to be associated with tumor
relapse and metastasis after standard treatment procedures8. On
the other hand, treatment-sensitive bulk tumor cells in the tumor
microenvironment may revert back to cells with CSC-like
properties through the process of EMT. Hence, elimination of
both the CSC-like population and the bulk tumor cells with
combination of a novel CSC targeting drug and conventional
chemotherapy is one current therapeutic strategy to improve
treatment outcome. In this study, we evaluated the combination
effect of ICG-001 with cisplatin on the growth of C666-1 cells. In
the MTT assay (Figure 6a), various concentrations of ICG-001 and
cisplatin were studied as a single agent or in combination on C666-
1 cells. The IC60 (inhibition of 60% of cell proliferation) of ICG-001
alone was 7.39 mM and of cisplatin alone was 2.51 mg/ml. In the
combination of ICG-001 with cisplatin, the IC60 of ICG-001 and
cisplatin was 1 mM and 1.5 mg/ml, respectively. The calculated
combination index (CI) was 0.7, indicating the synergistic
inhibitory effect of ICG-001 and cisplatin on C666-1. The
combined growth inhibitory effect of 1 mM ICG-001 with 1.5 mg/
ml cisplatin was further confirmed by counting the number of
viable cells in the cell culture (Figure 6b). Combined treatment
of ICG-001 with cisplatin exhibited a greater significant growth
inhibitory effect in C666-1 than either drug treatment alone
(*p,0.05).
Figure 4 | The role of SOX2 in tumor sphere formation. Transfection of C666-1 with SOX2 siRNA led to (a) decreased SOX2 expression and
(b) decreased number and size of tumor sphere formation. Results were expressed as themean6 S.D. of three experiments; *p, 0.05; **p, 0.02. The gels
have been run under the same experimental conditions. The full-length blots are presented in the supplementary Figure S2.
www.nature.com/scientificreports
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Combination of ICG-001 and cisplatin significantly suppressed
tumor growth in EBV-positive NPC xenografts. Next, we studied
the combined effect of ICG-001 with cisplatin in the C666-1 and
xeno-2117 xenograft models. C666-1 cells and xeno-2117 were
subcutaneously inoculated into the right flanks of nude mice,
respectively. When the xenografts became palpable, 50 mg/kg/day
ICG-001 was delivered via a subcutaneous osmotic minipump
implanted into the left flanks of the mice. A previously determined
sub-optimal dose of cisplatin (3.5 mg/kg/week for C666-1 xenografts
and 3 mg/kg/week for xeno-2117 xenografts) was delivered once per
week via i.p. injection. PBS delivered via the minipump was used as
the ICG-001 vehicle control. 3.3% DMF in saline delivered by i.p.
Figure 5 | Restoration ofmiR-145 by ICG-001 and the role ofmiR-145 in suppression of SOX2 and tumor sphere formation. (a) Expression ofmiR-145
in ICG-001-treated EBV-positive and -negative NPC cell lines. (b) SOX2 3’UTR Luciferase reporter assay. (c) and (d) Transfection of miR-145 precursor
suppressed SOX2 protein expression and reduced number and size of tumor sphere formed in ultralow attachment plate. Results were expressed as the
mean 6 S.D. of three experiments; *p , 0.05; **p , 0.02. The gels have been run under the same experimental conditions. The full-length blots are
presented in the supplementary Figure S3.
www.nature.com/scientificreports
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injection once per week was used as the cisplatin vehicle control.
The tumor volumes were measured twice weekly and the results
were plotted as the average tumor volume versus number of days
post-treatment. Results in Figure 7a showed the average tumor
volume of C666-1 and xeno-2117 xenografts. For both of the
xenograft models, the vehicle control group showed the largest
average tumor volume at the end of experiment. Slight tumor
suppression was observed in the ICG-001 alone group (C666-1
xenograft, p50.16; xeno-2117, p50.06) and cisplatin alone
treatment groups (C666-1 xenograft, p50.13; xeno-2117, p50.18).
A significant tumor suppression was observed in the combination of
ICG-001 and cisplatin treatment group (C666-1 xenograft, p50.02;
Figure 6 | Combination of ICG-001 and cisplatin showed a synergistic growth inhibitory effect on C666-1 cells. (a) MTT assay showing the percentage
of cell proliferation after 7 days treatment with various concentrations of ICG-001 and cisplatin. When comparing the IC60, the calculated CI value is 0.7,
indicating a synergistic growth inhibitory effect of ICG-001 and cisplatin. (b) Cell growth assay showing the total number of proliferating cells counted on
day-7 after ICG-001 and cisplatin drug treatment. Combination of ICG-001 and cisplatin showed a greater significant growth inhibitory effect in C666-1
than either drug treatment alone. Results are expressed as the mean 6 S.D. of three experiments; *p , 0.05.
www.nature.com/scientificreports
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Figure 7 | Combination of ICG-001 and cisplatin significantly suppressed tumor growth in EBV-positive NPC xenografts. (a) C666-1 cells and
xeno-2117 were subcutaneously injected into the right flanks of nude mice, respectively (n54 for C666-1 xenograft and n55 for xeno-2117). Drug
treatments were started when the tumors became palpable, and the size of tumors was measured twice weekly and plotted as the average tumor volumes
versus number of days post-treatment. (b) Percentage change of mouse body weight measured throughout the experiment. (c) Photos of tumor-bearing
mice and tumors dissected from mice at the end of experiment.
www.nature.com/scientificreports
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xeno-2117, p50.004). The weight of the mice was also measured
twice weekly and the change of mouse body weight was plotted in
7b. For C666-1 xenografts, the vehicle control group, ICG-001 alone
treatment group and combination treatment group showed a steady
increase in the body weight, while cisplatin alone treatment group
did not show any gain of body weight during the treatment period.
For xeno-2117, a steady increase of mouse body weight was observed
in the vehicle control group, ICG-001-alone, cisplatin-alone, and
combined treatment group. Combination of ICG-001 and cisplatin
significantly suppressed tumor growth in C666-1 and xeno-2117
xenografts without reduction of mouse body weight as compared
to the vehicle control mice. Figures 7c shows the images of tumor-
bearing mice and tumors dissected from mice at the end of
experiment.
Discussion
Cancer stem cells (CSCs) represent a subpopulation of cells within
the bulk tumor that have the capability to undergo self-renewal, drive
the tumor growth, and are resistant to radiation and conventional
drugs6–8. The residual CSCs after conventional treatment can lead to
tumor relapse in local and distant regions. Therapeutic targeting of
the CSC population may overcome the local relapse and distant
metastatic treatment failure in NPC. The existence of CSCs has
recently been identified in various types of solid tumors such as brain
tumor, breast cancer, ovarian cancer, and NPC32–35. In NPC, both
SOX2 and CD44 expression were found to be enriched in the CSC
population and serve as potential markers for the CSC population in
NPC27. In the present study, we demonstrated that the ICG-001 can
reduce the growth of tumor spheres and inhibit the production of the
SOX2hi/CD44hi CSC-like population in EBV-positive C666-1 NPC
cells. Compared with other tumors, C666-1 is relatively resistant to
cisplatin36. Here, we demonstrated that the combination of ICG-001
with cisplatin can effectively suppress tumor growth in the C666-1
and xeno-2117 xenograft models. These results strongly suggest
that combination of ICG-001 with cisplatin can enhance the tumor
suppressive effect in NPC cells.
Wnt, Notch, and Hedgehog are the three major signaling path-
ways regulating CSC growth and pluripotency10. These signaling
pathways may integrate and funnel down into a simple decision
point for CSCs to retain potency or initiate differentiation18. The
binding of nuclear b-catenin with its transcriptional coactivator
CBP is an important cell fate determination point for cells to main-
tain pluripotency or initiate differentiation18,23. By targeting this
final cell fate decision point using CBP/ b-catenin antagonists e.g.
ICG-001, we may alter the expression of multiple CSC-associated
proteins from different signaling pathways. CSC-associated proteins
such as SOX2, CD44, survivin, EGFR, FOXM1, and EZH2 have been
shown to play important roles in cell proliferation and maintenance
of stemness phenotypes28,37–41. SOX2 is one of the major stem cell
pluripotency transcription factors, essential for pluripotency in
embryonic stem cells28. In NPC, SOX2 has been shown to be
expressed in over 90% of tumor tissue and the expression is signifi-
cantly associated with a poorer distant metastasis-free survival42.
CD44 is membrane receptor for hyaluronic acid involved in a wide
range of cellular functions37. Both SOX2 and CD44 are found to be
enriched in the NPC CSC population with higher clonal and sphere
forming abilities27. Survivin is a directWnt targeted gene responsible
for cell proliferation and anti-apoptosis38. The decreased expression
of survivin is currently used as an on-target drug effect biomarker in
the clinical study of the second generation CBP/b-catenin antagonist
PRI-72418. EGFR is a tyrosine kinase receptor associated with NPC
poor prognosis, cell proliferation, migration, and drug resistance39.
Therapeutic targeting of EGFR inNPCusing cetuximab and gefitinib
are currently under clinical evaluations, however, the results are
still not promising43,44. FOXM1 is a member of Forkhead box
transcription factor family involved in self-renewal and stem cell
proliferation40. EZH2 is a component of the polycomb repressive
complex 2 that is essential in regulating embryonic development,
pluripotency and self-renewal41. Both FOXM1 and EZH2 have been
implicated as potential therapeutic targets for NPC and are the
downstream targets of EBV-activated Hedgehog signaling path-
way45–47. In the present study, ICG-001 was found to downregulate
the expression of these multiple essential CSC-associated proteins
and effectively reduce the CSC population.
Tumor sphere formation is a functional assay to enrich the
CSC-like cells under serum-free and ultralow attachment conditions.
This in vitro method closely mimics the in vivo tumor growth situ-
ation26. In the present study, we demonstrated that ICG-001 can
reduce tumor sphere formation with concomitant reduction of both
SOX2 and CD44 expression. The siRNA knockdown of SOX2 in
C666-1 significantly inhibited tumor sphere formation, indicating
the involvement of SOX2 in regulating the growth of the CSC-like
population in NPC. In a recent NPC CSC study, Lun et al. suggested
that the enrichment of SOX2 expression in tumor spheres may be
due to the loss of SOX2 repressing miRNAs27. miRNAs are short
noncoding RNAs that regulate gene expression post-transcription-
ally and have been recently been reported to regulate the expression
of stem cell maintenance factors48. In NPC, the expression of miR-
145 has been shown to be downregulated31 and miR-145 has also
been shown to be a SOX2 repressing miRNA in human embryonic
stem cells30. To further study the underlying mechanism of ICG-001
in the regulation of SOX2 expression, we examined the expression of
miR-145 after ICG-001 treatment. ICG-001 restored the expression
of miR-145 in both the EBV-positive and EBV-negative NPC cell
lines. Transfection of miR-145 precursor into C666-1 significantly
repressed SOX2 protein expression and tumor sphere formation.
This observation is in line with the previous studies that miR-145
can directly repress SOX2 protein expression, thereby reducing the
stem cell phenotype30,49. According to the miRNA target prediction
algorithms, there was a recent concern on the potential influence of
miR-145 on the protein expression of b-actin50, and, hence, affecting
the normalization of the SOX2 protein expression. In the present
study, the housekeeping protein GAPDH was used as an internal
control in the estimation of SOX2 expression, and, in fact, we did
not observe the repressive effect ofmiR-145 on the expression level of
b-actin.
Today, the standard treatment for NPC is radiotherapy or com-
bined chemo-radiotherapy mainly with cisplatin-based regimens4.
Patients often suffer from the toxic side effects of cisplatin and a
significant rate of chemoresistance contributes to NPC treatment
failure51. Since the CSC-like populations within the bulk tumor
are more resistant to conventional therapy8, there is a need to
identify drugs that can effectively target the CSC-like populations.
Combination of CSC targeting drugs with conventional therapy
offers a promising therapeutic strategy to overcome treatment failure
in NPC. In this study, we first demonstrated ICG-001 can effectively
reduce the CSC-like population in C666-1. Next, we showed the
combined tumor suppressive effect of ICG-001 with cisplatin in
C666-1. C666-1 was previously reported as a cisplatin-resistant cell
line27. Using a nude mouse tumorigenicity assay, we demonstrated
that cisplatin alone did not significantly suppress C666-1 xenograft
growth (p50.13). However, the combination of ICG-001 with cis-
platin significantly suppressed the growth of C666-1 xenografts
(p50.02). Also, the overall health condition of the ICG-001 treated
mice and importantly the combined treatment mice was better than
the cisplatin-alone treated mice. This data provided functional evid-
ence that the combination of ICG-001 with cisplatin could enhance
the tumor suppressive effect in NPC xenograft while at the same time
ameliorating some of the cisplatin toxicity. The combination of
ICG-001 with cisplatin is, therefore, safer and more efficacious for
the treatment of NPC tumors than cisplatin alone. PRI-724, a second
generation CBP/b-catenin antagonist, approximately 20 times more
www.nature.com/scientificreports
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potent than ICG-001 is currently being used in multiple clinical
studies. Phase Ia clinical studies of PRI-724 in advanced solid tumors
showed a very acceptable toxicity profile up to 905 mg/m2 for 7 day
i.v infusion to patients as reported at 2013 American Society of
Clinical Oncology (ASCO). A phase Ib trial of PRI-724 combined
with gemcitabine for refractory pancreatic cancer , a phase Ib trial of
PRI-724 combined with Folfox6 for refractory colorectal cancer, and
a phase I/II trial for leukemia are currently under evaluation18. Both
the pre-clinical and clinical evidence supports the safety and efficacy
of CBP/b-catenin antagonists in combination with conventional
drug treatment in cancer. Future clinical investigations of PRI724
combined with cisplatinmay benefit NPC patients providing a better
treatment outcome.
Conclusion
The presence of cancer stem cells is believed to be associated with
tumor relapse and metastasis after NPC standard treatments. Our
results suggest that ICG-001 can inhibit the growth of the CSC-like
population in EBV-positive NPC cells. ICG-001 can significantly
reduce the growth of tumor spheres and the population of spheroid
cells with a SOX2hi/CD44hi phenotype. Furthermore, the combina-
tion of ICG-001 with cisplatin demonstrated enhanced tumor sup-
pressive effects on the EBV-positive NPC cells and xenografts, which
may warrant further clinical study in NPC patients.
Methods
Chemical and antibodies. Primary antibodies SOX2, CD44, survivin, EGFR,
FOXM1, and EZH2 forWestern blotting analysis were purchased fromCell Signaling
(Danvers, MA). Primary antibody for E-cadherin was purchased from Invitrogen
(Carlsbad, CA). Primary antibodies for vimentin and GAPDH were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA), and b-actin was purchased from
Sigma-Aldrich (St. Louis, MO). Antibodies for immunofluorescence staining
Alexa FluorH 488 conjugated CD44 and Alex FluorH 647 conjugated SOX2 were
purchased from Cell Signaling (Danvers, MA).
Cell lines and xenograft.The EBV-positive NPC cell line, C666-1, wasmaintained in
RPMI-1640medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS) (Invitrogen, Carlsbad, CA) and 1% penicillin and streptomycin (P/S)
(Invitrogen, Carlsbad, CA)3. The EBV-negative NPC cell linesHONE1 andHK1were
maintained in DMEM medium supplemented with 5% FBS and 5% newborn calf
serum (NCS) with 1% P/S52,53. Cells were cultured at 37uC in a 5% CO2 humidified
incubator. The cell lines were authenticated by and obtained from the Hong Kong
NPC AoE Cell Line Repository. The EBV-positive NPC xenograft, xeno-2117, was
previously established from a NPC patient biopsy54 and was maintained
subcutaneously in athymic BALB/c nu/nu mice for in vivo study.
Cell growth assay. The cell growth assay was performed as previously described55.
In brief, C666-1 cells (3x105) were seeded onto 35mm culture dishes and treated with
ICG-001 (10 mM). On day-3, 5, and 7 after ICG-001 treatment, the number of viable
cells was determined and counted under inverted light microscope with trypan blue
exclusion staining. In the cell growth assay of ICG-001 combined with cisplatin,
C666-1 cells were treated with 1 mMICG-001 and/or 1.5 mg/ml cisplatin. The number
of viable cells was counted on day-7 after the drug treatment.
Cell transfection. Transient transfection was performed using Lipofectamine
Reagent 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
C666-1 cells (5x105) were seeded onto fibronectin-coated 35-mm dishes. For siRNA
knockdown, 50 nMON-TARGETplus SMARTpool Human SOX2 siRNA (a pool of 4
siRNA: GCUCUUGGCUCCAUGGGUU; UCAUGAAGAAGGAUAAGUA;
GCUUCUAGACCUACAUGAA; CAGUACAACUCCAUGACCA), or 50 nM
ON-TARGETplus siCONTROL Non-Targeting siRNA (Dharmacon, Lafayette, CO)
was transfected to C666-1. For miRNA precursor transfection, 50 nM pre-miR145
miRNA precursor or 50 nM pre-miR miRNA precursor control (Ambion, Austin,
TX) was transfected to C666-1. After 72 hours of transfection, cells were harvested for
expression analysis and tumor sphere formation assay.
Luciferase reporter assay. C666-1 cells were transiently transfected with 50 ng
pMirTarget luciferase reporter vector containing SOX2 3’UTR (Origene, Rockville,
MD) along with 200 nM pre-miR145 miRNA precursor or pre-miR miRNA
precursor control (Ambion, Austin, TX) using Lipofectamine Reagent 2000
(Invitrogen, Carlsbad, CA) mentioned above. The pMirTarget vector contains a red
fluorescent protein (RFP) for monitoring the transfection efficiency and
normalization. After 48 hours of transfection, the red fluorescent signal was captured
under microscopy and then the cells were lysed for measurement using firefly
luciferase reporter assay system (Promega, Valencia, CA) according to the
manufacturer’s manual. The luciferase activities were calculated and normalized to
intensity of RFP expression.
miRNA expression analysis. Total RNA was reverse-transcribed using TaqMan
MicroRNA Assay Kit with miRNA-specific stem-looped RT primer (Applied
Biosystems, Foster City, CA) according to the manufacturer’s protocol. Realtime
quantitative PCR was performed in Applied Biosystems StepOne Realtime PCR
Systems using TaqMan Universal PCR Master Mix and TaqMan MicroRNA Assay
primer (Applied Biosystems, Foster City, CA). Human U6 snRNA (RNU6B) was
used as the endogenous control. The fold change in expression level was calculated
using 2-DDCt method.
Western blotting analysis. Western blotting analysis was performed as previously
described56. In brief, cells were collected after 7 days of treatment, washed twice in
phosphate-buffered saline (PBS), and lysed in ice-cold lysis buffer containing 1%
phosphatase inhibitors cocktail (Calbiochem, San Diego, CA) and 0.25% protease
inhibitors cocktail (Sigma, St. Louis, MO). Protein samples were resolved on SDS–
polyacrylamide gel and transferred to PVDF membrane (Millipore, Billerica, MA).
After blocking with 5% non-fat milk, membrane was incubated with primary
antibodies (1:1000) and corresponding HRP-conjugated secondary antibodies
(1:4000). Western-blotting substrate (Labfrontier Co. Ltd., Bio Division) was added
to the membrane. The chemiluminescent signal was then detected and visualized on
the X-ray film. b-actin or GAPDH was probed as an internal control.
Tumor sphere formation assay and growth inhibition analysis on established
tumor spheres. Tumor sphere formation assay was performed as previously
described55. Cells were seeded in low cell density (2x103 cells/well) on a 24-well ultra-
low attachment plate (Corning, Acton, MA) in serum-free DMEM/F-12 (Invitrogen,
Carlsbad, CA) supplemented with 20 ng/ml EGF (Sigma, St. Louis, MO), 20 ng/ml
FGF (Cell Signaling, Danvers, MA), and 20 ng/ml IGF (Cell Signaling, Danvers, MA).
The cultures were fed with fresh serum-free DMEM/F12 and growth factors every
other day. ICG-001 (10 mM)was added to the culture on the first day of tumor sphere
culturing. After 7 days of incubation, the images of cells were captured and tumor
spheres having a diameter .20 mm were counted using Image J software. The total
number and diameter of tumor spheres formed in ICG-001-treated and -untreated
cultures were compared.
For studying the growth inhibitory effect of ICG-001 on established tumor spheres,
tumor spheres were allowed to grow for 7 days without any drug treatment, ICG-001
(10 mM) was then added to the established tumor sphere cultures and the cells were
incubated for a further 7 days. After incubation, the images of tumor spheres were
captured under an inverted microscope for size profile and mean diameter analysis.
Then the tumor spheres were harvested for immunofluorescence staining or fluor-
escence activated cell sorting (FACS) analysis.
Immunofluorescence staining. The expression of SOX2 and CD44 was determined
using immunofluorescence staining method as previously described55. Briefly, tumor
spheres were collected, fixed, permeabilized, and incubated with Alex FluorH
647 conjugated SOX2 and Alexa FluorH 488 conjugated CD44 antibodies.
The immunofluorescence images were captured using Olympus Fluoview
1000 confocal scanning laser microscope.
FACS analysis. Quantitative analysis of SOX2 and CD44 expression by the spheroid
cells was performed as previously described55. Briefly, the tumor spheres were
collected and resuspended in PBS. The spheroid cells were fixed in 1.6 %
paraformaldehyde, and permeabilized in ice-cold methanol. The cells were then
washed and resuspended in 0.5% bovine serum albumin (BSA) in PBS, and stained
with Alex FluorH 647 conjugated SOX2 and Alexa FluorH 488 conjugated CD44
antibodies. Respective mouse or rabbit IgG isotype controls were used as negative
controls. For each sample, at least 10,000 cells were acquired and analyzed by
FACSCalibur flow cytometer (Becton Dickinson, Franklin Lakes, NJ).
MTT assay. MTT assay was performed as previously described55. In brief, C666-1
cells (1x104) were seeded in triplicate in 96-well plate and incubated with various
concentrations of ICG-001 and cisplatin. After 7 days of incubation, MTT solution
(Sigma-Aldrich, St. Louis, MO) (0.25 mg/ml) was added and the optical density (OD)
was measured at absorbance 540nm with reference to absorbance 690 nm. The OD is
directly proportional to the number of proliferating cells and the percentage of cell
proliferation was calculated compared to control wells.
Analysis of combination index. The combination index (CI) was calculated using
the Chou and Talalay method CI 5 (D)1/(Dx)1 1 (D)2/(Dx)2 to determine the
combined drug effects57. (D)1 and (D)2 are the doses of drug-1 and drug-2 used in
combination that have x effect. (Dx)1 and (Dx)2 are the doses of drug-1 and drug-2
used alone that have x effect. The combined drug effect is considered as additive when
CI51, synergistic when CI,1, and antagonistic when CI .1.
Nude mouse tumorigenicity assay. For the C666-1 xenograft study, nude mice were
supplied by the Laboratory Animal Unit of the University of Hong Kong and housed
by Department of Clinical Oncology of Queen Elizabeth Hospital Hong Kong. All
procedures were conducted under license from theHongKongDepartment of Health
and approved by Committee on the Use of Live Animals in Teaching and Research
(CULTAR) at the University of HongKong. For the xeno-2117 study, nudemice were
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supplied and housed by Department of Anatomical and Cellular Pathology and State
Key Laboratory in Oncology in South China, The Chinese University of Hong Kong,
under license from the Hong Kong Department of Health and approved by the
Animal Experimentation Ethics Committee (AEEC) at The Chinese University of
Hong Kong. In brief, 1x107 C666-1 cells and an equal portion of xeno-2117 were
subcutaneously (s.c.) injected into right flank of female athymic BALB/c nu/nu mice
at 6-8 weeks of age, respectively. When the tumors reached 100mm3 for C666-1 and
became palpable for xeno-2117, respectively, the mice were divided into four groups
(n54) for C666-1 xenograft and five (n55) for xeno-2117 for subsequent treatment
either with drug vehicle control, ICG-001 alone (50 mg/kg/day dissolved in PBS),
cisplatin alone (3.5 mg/kg/week dissolved in 3.3% DMF in saline for C666-1
xenografts and 3 mg/kg/week dissolved in 3.3% DMF in saline for xeno-2117), or
combined ICG-001 (50 mg/kg/day dissolved in PBS) with cisplatin (3.5 mg/kg/week
dissolved in 3.3%DMF in saline for C666-1 xenografts and 3mg/kg/week dissolved in
3.3% DMF in saline for xeno-2117). For stable and continuous delivery of ICG-001,
osmotic minipumps Alzet Model 1004 (DURECT Corporation, Cupertino, CA) were
s.c. implanted to the left flanks of the ICG-001 treatment and combined treatment
group of mice according to manufacturer’s instructions. Osmotic minipumps
containing PBS as ICG-001 solvent control were s.c. implanted to vehicle control
group and cisplatin treatment group. The day of osmoticminipump implantationwas
referred as day 0. Three days post-tansplantation, cisplatin was administrated by
intraperitoneal (i.p.) injection to cisplatin treatment group and combined treatment
group weekly. For vehicle control group and ICG-001 treatment group, 3.3%DMF in
saline was administrated by i.p. injection weekly as cisplatin solvent control. The
tumor volume in mm3 (length x width x height) and the mice body weight were
measured twice weekly, until tumor volume in control group became too large for the
mouse.
Statistical analysis. All results were representative results from at least three
independent experiments. Error bars in each data point represented the arithmetic
mean 6 SD of three replicates (n 5 3). The p-values were calculated by Student’s
t-test, p , 0.05 was considered as statistically significant.
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